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Abstract
Pancreatic cancer has the worst prognosis of any major malignancy, with an annual death rate that approximates
the annual incidence rate. Delayed diagnosis, relative chemotherapy and radiation resistance and an intrinsic bio-
logic aggressiveness all contribute to the abysmal prognosis associated with pancreatic cancer. Answers to the
frustrating effort to find effective therapies for pancreatic cancer may be gained through a renewed perspective on
tumorigenesis as a process governed by a select population of cells, termed cancer stem cells (CSCs). Cancer
stem cells, like their normal counterparts, have the properties of self-renewal and multilineage differentiation
and possess inherently heightened DNA damage response and repair mechanisms that make them difficult to
eradicate. Initially discovered in leukemias, researchers have identified CSCs in several solid-organ malignancies
including breast, brain, prostate, and colon cancers. We have recently identified a CSC population in human pan-
creatic cancers. These pancreatic CSC represent 0.5% to 1.0% of all pancreatic cancer cells and express the cell
surface markers CD44, CD24, and epithelial-specific antigen. Pancreatic CSCs have been shown to be resistant to
standard chemotherapy and radiation, and devising specific therapies to target this distinct cell population is likely
needed to identify effective therapies to treat this dismal disease.
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Introduction
Pancreatic cancer is a highly lethal disease, which is usually diagnosed
in an advanced state for which there are little or no effective thera-
pies. Attempts to better understand the molecular characteristics of
pancreatic cancer have focused on studying gene and protein expres-
sion profiles of samples of pancreatic cancer. However, these studies
have not taken into account the heterogeneity of cancer cells present
within a particular tumor. Emerging data have shown that malignant
tumors are quite heterogeneous and that they are composed of a
small subset of distinct cancer cells (usually defined by cell surface
marker expression) that are responsible for tumor initiation and
propagation, termed cancer stem cells (CSCs), and of more differen-
tiated cancer cells, which have very limited proliferative potential.
These cells are called CSCs because, like their normal counterparts,
they possess the ability to self-renew and produce differentiated prog-
eny. Cancer stem cells have now been identified in several solid tumor
types, including breast, brain, prostate, and colon cancers [1–5].
Isolation of Pancreatic CSCs
The existence of CSCs was first observed in hematopoietic malig-
nancies. More than a decade ago, John Dick’s group at the University
of Toronto observed that rare subpopulations of cells within leuke-
mia are able to generate leukemia in nonobese diabetic–severe com-
bined immunodeficient (NOD-SCID) mice [6]. These cells were
discriminated by the surface marker expression CD34+CD38− and
displayed properties of self-renewal and multilineage differentiation
along with potent proliferative capacity. The technique of sorting
cells based on cell surface marker expression and dilutional tumor-
initiation assays assessing the ability of subsets of cancer cells to pro-
duce tumor xenografts in immunocompromised NOD-SCID mice
was also applied to investigate the possible existence of solid-organ
CSCs. Using these techniques, the first solid-organ CSC was isolated
from breast cancers by Al-Hajj et al. [1]. Using the markers CD44,
CD24, and epithelial-specific antigen (ESA), which are known to be
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intimately involved in cell–cell adhesion with multiple signaling func-
tions [7–9], the investigators determined that the cancer cell popula-
tion expressing the markers CD44+ESA+CD24−/low was capable of
re-creating a breast cancer with all its in vivo complexity with as few
as 100 cells. Unsorted breast cancer cells and CD44+CD24+ cells from
breast cancer specimens did not contribute to de novo tumorigenesis
[2]. Further studies of these breast CSCs showed activation of path-
ways that govern self-renewal in normal stem cells, including the
hedgehog signaling pathway and the polycomb gene family member
(BMI-1) [10].
As in breast cancer, FACS analysis revealed heterogeneous surface
marker expression for CD44, CD24, and ESA among pancreatic
tumor cells. To prove that distinct subpopulations were responsible
for tumor initiation in pancreatic cancer, FACS-sorted pancreatic can-
cer cells were derived directly from patient’s primary tumors or primary
tumors established as low-passage xenografts in NOD-SCID mice.
Cells were sorted for the markers CD44, CD24, and ESA, both in-
dividually or in combination, and were injected into mice, and their
tumorigenic potential was assessed. In a dose–response analysis of un-
sorted pancreatic cancer cells (102-104) injected per mouse, no tumor
growth was evident at 16 weeks unless at least 104 cells were injected,
where four of six mice developed tumors. For cancer cells sorted for
the markers CD44, CD24, and ESA, the expression of these individ-
ual markers identified cell populations with enhanced tumorigenic
potential (Table 1). Injection of cancer cells expressing dual marker
combinations (CD44+ESA+, CD24+ESA+, and CD44+CD24+) re-
sulted in further enhanced tumorigenic potential compared with sin-
gle marker–sorted cells, with more tumors forming with injection of
as few as 100 cells, and no tumors forming in marker-negative cells
until at least 103 cells were injected. The sorted cell population with the
highest tumorigenic potential expressed all of the markers CD44,
CD24, and ESA, with CD44+CD24+ESA+ pancreatic cancer cells com-
prising only 0.2% to 0.8% of all pancreatic cancer cells. Six of 12 ani-
mals injected with 100 CD44+CD24+ESA+ cells formed tumors,
whereas cells negative for expression of these cell surface markers did
not develop any tumors until 104 CD44−CD24−ESA− cells were in-
jected, when only 1 of 12 animals developed a tumor (Table 1). Thus,
pancreatic cancer cells expressing the cell surface markers CD44, CD24,
and ESA had at least a 100-fold increased tumorigenic potential com-
pared with nontumorigenic cells [11]. The percentage of pancreatic can-
cer cells expressing these cell surface markers in individual tumors was
maintained on passaging in NOD-SCID mice.
CD44+CD24+ESA+ pancreatic cancer cells’ ability to recapitulate
the primary tumor of origin in its entirety was verified by histology.
Tumors derived from CD44+CD24+ESA+ pancreatic cancer cells
were remarkably similar in appearance to the patient’s primary tumor
and also had similar patterns of expression of the pancreatic adeno-
carcinoma markers S100P and stratifin (Figure 1). The FACS surface
marker expression pattern of xenografts derived from CD44+CD24+
ESA+ cells paralleled the phenotypic diversity characterized in the
original tumor, further verifying that CD44+CD24+ESA+ pancreatic
cancer cells have the capacity to both self-renew and produce differ-
entiated progeny [11].
Another discriminating cell surface marker that enriches for popu-
lations of CSCs in both brain and colon cancer is CD133 [3–5]. In a
study by Hermann et al. [12], they found that a small but distinct
population of pancreatic cancer cells expresses CD133 and enriches
for cells with potent tumor-initiating capacity. CD133+ cells com-
prised 1% to 3% of pancreatic adenocarcinoma cells analyzed in their
study. In comparison to CD133− and bulk pancreatic cancer cells,
as few as 500 CD133+ cells injected in immunocompromised mice
generated xenografts with the phenotype of the primary pancreatic
cancer of origin. Interestingly, their report states that there was ap-
proximately 14% overlap between CD44+CD24+ESA+ and CD133+
cells [12]. These findings suggest that more than one set of specific
cell surface markers may enrich for pancreatic CSC populations and
that a more distinguishing expression marker or set of markers to
identify pancreatic CSCs may yet to be discovered (Table 2).
Self-renewal Pathways in Pancreatic CSCs and
Therapeutic Implications
Self-renewal and differentiation potential are features of stem cells.
Self-renewal allows normal stem cells to persist during the lifetime of
the organism, and differentiation of stem cells provides the progenitors
and mature cells for tissue genesis, maintenance, and regeneration after
stress or injury. Pathways that are important for self-renewal in normal
stem cells are often found to be dysregulated in human cancers [13].
Table 1. Tumor Formation Ability of Sorted Pancreatic Cancer Cells Using Cell Surface Markers.
Marker/Cell Number 104 103 500 100
Unsorted 4/6 0/6 0/3 0/3
CD24+ESA+ 6/8 5/8 5/8 2/8
CD24−ESA− 2/8 1/8 0/8 0/8
CD44+/CD24+/ESA+ 10/12 10/12 7/12 6/12
CD44−/CD24−/ESA− 1/12 0/12 0/12 0/12
Figure 1. Tumor formation in NOD-SCID mice injected with pancre-
atic cancer stem cells. Implantation of 500 CD44+CD24+ESA+ pan-
creatic CSCs results in tumor formation (top panel). Expression of
the proteins S100P (middle two panels) and stratifin (bottom two
panels) is similar in the tumor generated from CD44+CD24+ESA+
cells and the patient’s primary tumor.
Table 2. Cell Surface Markers Used to Identify Pancreatic CSCs.
1. CD44+/CD24+/ESA Li et al. [11]
2. CD133+ Hermann et al. [12]
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Self-renewal signaling pathways that have been implicated in solid-
organ malignancies include Notch, Wnt/β-catenin, phosphatase and
tensin homologue deleted from chromosome 10, sonic hedgehog
(SHH), and BMI-1 [10,14–18]. To assess whether upregulation of
molecules important in self-renewal pathways occurred in pancreatic
cancer cells, we performed real-time reverse transcription–polymerase
chain reaction to assess the expression of developmental signaling
molecules. We observed that the SHH transcript was elevated 4-fold
in CD44−CD24−ESA− nontumorigenic pancreatic cancer cells and
46-fold in CD44+CD24+ESA+ pancreatic cancer cells when compared
with normal pancreatic epithelial cells (Figure 2). These data suggested
that there is significant upregulation of SHH in pancreatic CSC that
persists, albeit at a much lower level, in the differentiated progeny [11].
It has been shown in other studies that human pancreatic adenocar-
cinomas display increased activation of the hedgehog pathway [18,19].
Transgenic overexpression of SHH within the pancreas results in the
development of pancreatic cancer precursor lesions, termed PanIN le-
sions, accumulation of genetic mutations commonly seen in pancreatic
cancer, including K-ras mutations, and upregulation of Her2/neu. In-
hibition of hedgehog signaling by cyclopamine inhibited pancreatic
cancer growth both in vitro and in vivo, suggesting that this signaling
pathway has an early and critical role in pancreatic cancer development.
Overexpression of the polycomb gene family member protein BMI-1
has been shown to contribute to the invasive potential of epithelial ma-
lignancies including breast, brain, colon, and oral cancers [20–23]. An
important recent revelation was the finding that BMI-1 is crucial for the
maintenance and self-renewal in both normal stem cells [24–26] and
CSCs [10,27]. There are no published reports investigating the func-
tional role of BMI-1 in pancreatic cancer. We observed that BMI-1 is
significantly elevated in CD44+CD24+ESA+ pancreatic CSCs com-
pared to their differentiated CD44−CD24−ESA− pancreatic cancer cell
counterparts, suggesting that BMI-1 may play a role in the mainte-
nance of self-renewal in this pancreatic CSC population (Figure 2).
The Role of Pancreatic CSCs in Tumor Metastasis
The cytokine receptor CXCR4 is expressed in hematopoietic stem
cells and interacts with the ligand stromal cell–derived factor 1 (SDF-1)
that is secreted by bone marrow stromal cells. This chemotactic signal-
ing cascade is responsible for the homing of hematopoietic cells to the
bone marrow. The CXCR4 cytokine is also overexpressed in advanced
and metastatic breast cancers and may play a key role in cancer cell
mobility [28,29]. CXCR4 has also been found to be overexpressed
in advanced pancreatic cancer samples [30]. Hermann et al. [12] re-
cently explored the relationship between pancreatic CSCs and CXCR4
and found that CD133+ pancreatic CSC present at the invading front
of pancreatic cancers showed high expression levels of CXCR4. Inter-
estingly, whereas CD133+CXCR4− and CD133+CXCR4+ cells were
able to form primary tumors equally, only CD133+CXCR4+ cells were
able to metastasize [12]. The results of this study suggest that there are
stationary and migratory forms of pancreatic CSCs. Importantly, abro-
gation of CXCR4 signaling prevented metastasis in this tumor model.
These findings may have clinical implications when considering strate-
gies to inhibit metastasis of pancreatic CSCs.
Therapeutic Consequences of Pancreatic CSCs
A practical consequence of CSC heterogeneity is that strategies to
induce cell death to treat cancer must address the unique survival
mechanisms of the CSC within the cancer cell population. Most tra-
ditional cancer treatments have been developed and assayed based on
their ability to kill most of the cancer cell population and result in
tumor shrinkage. These treatments likely miss the CSCs, which have
been shown in several cancer types to be quite resistant to standard
chemotherapy and radiation. A prediction of the CSC model is that
treatments that target the CSC will be required to result in an effec-
tive cure of cancer. As such, tumor shrinkage is not going to be a
useful parameter to measure effectiveness of CSC therapies, and ap-
proaches to measure CSC burden will need to be devised.
Studies in CD34−CD38− leukemic stem cells showed that these leu-
kemic CSCs were significantly less sensitive to daunorubicin or cyta-
rabine than bulk leukemic cells [31]. In glioblastoma, it was determined
that the CSC population expressing CD133+ in both primary tumors
and xenografts was enriched two- to four-fold following ionizing radi-
ation [32]. Enrichment of the CD133+ brain CSC occurred due to in-
herent resistance of this distinct population to radiation-induced
apoptosis. The ability of the CSC to resist apoptosis-induced radiation
was conferred by the preferential activation of DNA damage response
Figure 2. Upregulation of developmental signaling molecules in pancreatic CSCs. mRNA expression of SHH (A) and BMI-1 (B) in normal
pancreas, nontumorigenic CD44−CD24−ESA− pancreatic cancer cells, and highly tumorigenic CD44+CD24+ESA+ pancreatic CSCs.
Total RNA was quantitated by real-time reverse transcription–polymerase chain reaction. Data are expressed as the mean ± SE. *P <
.05 versus normal pancreas.
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in these cells [32]. In a recent report, Hermann et al. [12] showed that
CD133+ pancreatic CSCs are resistant to standard chemotherapy.
Some studies suggest that Wnt/β-catenin signaling leads to in-
creased tolerance of DNA damage, thus conferring radiation resistance
of CSCs [33–35]. Wnt signaling activates the DNA damage response,
and one transcriptional target of β-catenin signaling is survivin, which
is known to promote cellular survival in pancreatic cancer in response
to apoptotic stimuli such as ionizing radiation [36]. The complex na-
ture of CSC survival mechanisms extends beyond Wnt/β-catenin sig-
naling. Notch activity has also been implicated in breast cancer’s
response to radiation injury [37], and targeting this pathway has
shown effective antitumor response in preclinical trials [38]. Alterna-
tively, some studies suggest that the level of compaction of chromatin
dictates accessibility to genomic DNA and subsequent mediation of
DNA damage responses and that a looser configuration of chromatin
in stem cells leads to accelerated DNA repair following injury. Such
has been shown in embryonic stem cells that have lower levels of
the chromatin structural protein histone-1. In a study by Murga
et al. [39], embryonic stem cells with lower levels of histone-1, which
results in less chromatin compaction, had enhanced recovery from
DNA damage in comparison to differentiated cells. Pancreatic CSCs
likely share some of the signaling cascades involved in cellular re-
sponses to DNA damage present in other stem cell systems; however,
the specific responses and mechanisms involved in the chemotherapy
and radiation resistance of pancreatic CSCs remain to be elucidated.
Microenvironmental Cues
The stromal epithelial interactions that occur in the stem cell niche
of cancers have profound implications in understanding the complex
processes involved in tumor initiation, propagation, and metastasis.
Pancreatic cancer is noted for its profound desmoplasia. Although
CSCs have inherent defense mechanisms to radiation and chemother-
apy, the robust desmoplasia in pancreatic cancer likely provides a mi-
lieu for additive resistance. Supporting this possibility is a recent report
that demonstrated that the addition of conditioned media of pancre-
atic cancer–associated fibroblasts to cultures of pancreatic cancer cells
inhibited the response of the cancer cells to chemotherapy and radia-
tion study [40].
Pancreatic cancers have been demonstrated to be quite hypoxic, and
CSCs may be enriched in areas of hypoxia, which promotes stem cell
maintenance and blocks differentiation [41]. Hypoxia induces chemo-
kines such as hypoxia-inducible factor 1, which upregulates vascular
endothelial growth factor and thus promotes tumor angiogenesis
[42]. Hypoxia-inducible factor 1 is also implicated in tumor responses
to radiation injury through induction of metabolic pathways, activa-
tion of p53 signaling, and induction of tumor proliferation [43].
The expression of hypoxia-inducible factor 1 and vascular endothelial
growth factor was observed to be significantly upregulated in pancre-
atic cancer [44]. The interaction of pancreatic CSC and the hypoxic
tumor microenvironment is a fertile area for future investigation.
Understanding microenvironmental cues will be important when
considering CSC therapeutics. It is likely that the best preclinical
model system to test CSC therapeutics will be primary pancreatic
cancers established in the orthotopic location, that is, the pancreatic
niche. This model system will not only mimic the heterogeneity of
tumors seen in actual patients but will also allow the contribution of
the tumor microenvironment, thus will allow assessment of the thera-
peutic responses in a clinically relevant setting.
Conclusions
Evidence suggests that pancreatic cancer is a CSC-driven disease.
Isolation and characterization of pancreatic CSCs reveal that these
tumor-initiating cells share important molecular pathways seen in other
solid-organ CSCs and contribute to resistance to conventional chemo-
therapy and radiation. A better understanding of the pathways govern-
ing the key properties of self-renewal, differentiation, and interactions
between pancreatic CSCs and the tumor microenvironment will ulti-
mately aid in the development of more effective therapeutics against
pancreatic cancer.
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